Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Recurrent Breast Cancer
Interventions: DRUG: Trastuzumab|BIOLOGICAL: NK immunotherapy
Sponsor: Fuda Cancer Hospital, Guangzhou
Collaborators: Shenzhen Hank Bioengineering Institute